Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
Total Valuation
TransMedics Group has a market cap or net worth of $4.48B. The enterprise value is $4.63B.
Market Cap$4.48B
Enterprise Value$4.63B
Share Statistics
TransMedics Group has 34,174,324 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding34,174,324
Owned by Insiders3.57%
Owned by Institutions10.20%
Financial Efficiency
TransMedics Group’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 4.98%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.98%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee606.51K
Profits Per Employee48.71K
Employee Count728
Asset Turnover0.55
Inventory Turnover3.85
Valuation Ratios
The current PE Ratio of TransMedics Group is 51.5. TransMedics Group’s PEG ratio is -0.24.
PE Ratio51.5
PS Ratio4.69
PB Ratio9.06
Price to Fair Value9.06
Price to FCF-25.60
Price to Operating Cash Flow26.57
PEG Ratio-0.24
Income Statement
In the last 12 months, TransMedics Group had revenue of 441.54M and earned 35.46M in profits. Earnings per share was 1.07.
Revenue441.54M
Gross Profit262.08M
Operating Income37.50M
Pretax Income35.78M
Net Income35.46M
EBITDA69.95M
Earnings Per Share (EPS)1.07
Cash Flow
In the last 12 months, operating cash flow was 177.99M and capital expenditures -57.34M, giving a free cash flow of 120.65M billion.
Operating Cash Flow177.99M
Free Cash Flow120.65M
Free Cash Flow per Share3.53
Dividends & Yields
TransMedics Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.06
52-Week Price Change97.43%
50-Day Moving Average126.12
200-Day Moving Average111.74
Relative Strength Index (RSI)44.32
Average Volume (3m)911.09K
Important Dates
TransMedics Group upcoming earnings date is Mar 4, 2026, After Close (Confirmed).
Last Earnings DateOct 29, 2025
Next Earnings DateMar 4, 2026
Ex-Dividend Date―
Financial Position
TransMedics Group as a current ratio of 8.30, with Debt / Equity ratio of 146.21%
Current Ratio8.30
Quick Ratio7.52
Debt to Market Cap0.25
Net Debt to EBITDA2.60
Interest Coverage Ratio2.60
Taxes
In the past 12 months, TransMedics Group has paid 316.00K in taxes.
Income Tax316.00K
Effective Tax Rate<0.01
Enterprise Valuation
TransMedics Group EV to EBITDA ratio is 32.22, with an EV/FCF ratio of -27.84.
EV to Sales5.10
EV to EBITDA32.22
EV to Free Cash Flow-27.84
EV to Operating Cash Flow46.18
Balance Sheet
TransMedics Group has $466.17M in cash and marketable securities with $519.35M in debt, giving a net cash position of -$53.17M billion.
Cash & Marketable Securities$466.17M
Total Debt$519.35M
Net Cash-$53.17M
Net Cash Per Share-$1.56
Tangible Book Value Per Share$6.47
Margins
Gross margin is 60.28%, with operating margin of 8.49%, and net profit margin of 8.03%.
Gross Margin60.28%
Operating Margin8.49%
Pretax Margin8.10%
Net Profit Margin8.03%
EBITDA Margin15.84%
EBIT Margin11.37%
Analyst Forecast
The average price target for TransMedics Group is $147.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$147.00
Price Target Upside15.94% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast41.20%
EPS Growth Forecast173.53%